for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Shenzhen Salubris Pharmaceuticals Co Ltd

002294.SZ

Latest Trade

23.66CNY

Change

-0.19(-0.80%)

Volume

4,826,523

Today's Range

23.51

 - 

23.95

52 Week Range

19.75

 - 

29.20

As of on the Shenzhen Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
23.85
Open
23.86
Volume
4,826,523
3M AVG Volume
98.51
Today's High
23.95
Today's Low
23.51
52 Week High
29.20
52 Week Low
19.75
Shares Out (MIL)
1,046.02
Market Cap (MIL)
24,508.15
Forward P/E
19.35
Dividend (Yield %)
3.41

Next Event

Shenzhen Salubris Pharmaceuticals Co Ltd at Macquarie China Healthcare Corporate Day

Latest Developments

More

Shenzhen Salubris Pharmaceuticals' H1 Net Profit Down 19.9% Y/Y

Shenzhen Salubris Pharmaceuticals Says Q1 Net Profit Down 22.6 Percent Y/Y

Shenzhen Salubris Pharmaceuticals Says 2018 Net Profit Up 0.44 Pct

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Shenzhen Salubris Pharmaceuticals Co Ltd

SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. is a China-based company, principally engaged in the research and development, manufacture and distribution of pharmaceuticals. The Company provides two categories of products: pharmaceutical preparation and bulk drugs. The Company is also engaged in the research and development, production and sales of cardiovascular medical devices. The Company distributes its products within domestic market and to overseas markets.

Industry

Major Drugs

Contact Info

F37, Main Building,Chegong Temple

Lvgem NEO Square,No.6009 Shennan Boulvrd

Futian District

+86.755.83867888

http://www.salubris.cn/

Executive Leadership

Chenghai Ye

Chairman of the Board

Jun Liu

Finance Director

Kevin Sing Ye

General Manager, Director

Jie Yan

Deputy General Manager, Director

Ping Chen

Deputy General Manager

Key Stats

2.50 mean rating - 8 analysts
Sell
Hold
Buy
Revenue (MM, CNY)

2016

3.8K

2017

4.2K

2018

4.7K

2019(E)

4.8K
EPS (CNY)

2016

1.330

2017

1.390

2018

1.390

2019(E)

1.211
Price To Earnings (TTM)
18.84
Price To Sales (TTM)
5.17
Price To Book (MRQ)
3.80
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
5.60
LT Debt To Equity (MRQ)
3.32
Return on Investment (TTM)
20.09
Return on Equity (TTM)
18.09

Latest News

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up